Skip to main content
SpringerLink
Log in

Prevention of diabetes and left ventricular hypertrophy with AT1 receptor blockade fo hypertension

  • Clinical Trials Report
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zanolla L, Vassanelli C: Reducing diabetes incidence through the inhibition of the renin-angiotensin system: a strategy for reducing cardiovascular mortality and morbidity? J Cardiovasc Med (Hagerstown) 2007, 8:473–482.

    Google Scholar 

  2. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  3. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  4. Weber MA: Clinical trails report: putting LIFE into hypertension. Curr Hypertens Rep 2002, 4:275–277.

    Article  PubMed  Google Scholar 

  5. Schillaci G, Pirro M, Mannarino E: Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone? Hypertension 2007, 50:851–853.

    Article  PubMed  CAS  Google Scholar 

  6. Okin PM, Devereux RB, Gerdts E, et al.: Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006, 113:1588–1596.

    Article  PubMed  CAS  Google Scholar 

  7. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905–912.

    Article  PubMed  CAS  Google Scholar 

  8. Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201–207.

    Article  PubMed  CAS  Google Scholar 

  9. Serne EH, Stehouwer CD, ter Maaten JC, et al.: Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 1999, 99:896–902.

    PubMed  CAS  Google Scholar 

  10. Moan A, Risanger T, Eide I, Kjeldsen SE: The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994, 3:185–188.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Robert M. Carey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carey, R.M. Prevention of diabetes and left ventricular hypertrophy with AT1 receptor blockade fo hypertension. Current Science Inc 10, 91–92 (2008). https://doi.org/10.1007/s11906-008-0018-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-008-0018-x

Keywords

Search

Navigation